This CME-accredited activity explores the evolving treatment landscape of advanced and metastatic soft tissue sarcomas through high-yield clinical cases. Using interactive questions and evidence-based rationales, participants will enhance their ability to make therapeutic decisions involving chemotherapy, targeted therapy, immunotherapy, and surgical considerations across a spectrum of sarcoma subtypes.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Varun Monga (MD)
Dr. Varun Monga is an Associate Clinical Professor at UCSF. He did his medical school at Rajiv Gandhi Medical College, Thane India and completed his Internal Medicine Residency and an additional chief year at Rosalind Franklin University of Medicine and Sciences, North Chicago, IL. He then joined University of Iowa as an associate and worked as a hospitalist in Hematology, Oncology and BMT unit. Varun then stayed on to do his Hem/Onc fellowship at Iowa followed by a faculty position for over 7 years where he focused on clinical research and treatment of Primary CNS Tumors and Sarcomas. He recently moved to UCSF in April 2024 where his clinical focus is on sarcomas and Phase 1 clinical trials.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Amgen Topic: Industry contract with the institution Relationship end date: 04/14/2023 Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Cogent Biosciences Topic: Industry contract with the institution Relationship end date: 04/14/2023 Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Prelude Therapeutics Topic: Industry contract with the institution Relationship end date: 04/14/2023 Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Orbus Therapetuics Topic: Industry contract with the institution Relationship end date: 04/14/2023 Attribution: Other Type of financial relationship: Grant Or Contract Ineligible company: Oblato Therapeutics Topic: Industry contract with the institution Relationship end date: 04/14/2023
- Hematologists
- Oncologists
- Surgeons
- Radiation Oncologists
- Physician Assistants/Nurse Practitioners
- Pharmacists
Target Audience
- Apply current evidence to select appropriate systemic therapies for advanced and metastatic soft tissue sarcomas.
- Identify actionable mutations and biomarkers that guide targeted treatment decisions in sarcoma.
- Evaluate clinical scenarios to differentiate when surgery, radiation, or medical therapy is the preferred treatment approach.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: